Leerink Partnrs Has Pessimistic Outlook of VRTX Q2 Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings estimates for Vertex Pharmaceuticals in a note issued to investors on Wednesday, June 25th. Leerink Partnrs analyst D. Risinger now anticipates that the pharmaceutical company will post earnings per share of $3.59 for the quarter, down from their prior estimate of $3.78. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. Leerink Partnrs also issued estimates for Vertex Pharmaceuticals’ Q4 2025 earnings at $4.87 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The company had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period last year, the business earned $4.76 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis.

Several other analysts also recently weighed in on VRTX. Morgan Stanley reduced their target price on Vertex Pharmaceuticals from $464.00 to $460.00 and set an “equal weight” rating for the company in a report on Friday, June 20th. HC Wainwright reiterated a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday. Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, March 11th. Finally, Bank of America increased their price target on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a research note on Monday, March 31st. Fourteen research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $513.14.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $443.40 on Friday. The company has a fifty day moving average of $455.45 and a two-hundred day moving average of $459.02. The company has a market capitalization of $113.87 billion, a PE ratio of -113.11 and a beta of 0.41. Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals in the first quarter worth $25,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $31,000. Flaharty Asset Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at about $32,000. Finally, Truvestments Capital LLC increased its holdings in shares of Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.